Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity
暂无分享,去创建一个
[1] B. Abraham,et al. Fecal calprotectin: controlling the cost of care. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] Kori L Wallace,et al. Immunopathology of inflammatory bowel disease. , 2014, World journal of gastroenterology.
[3] J. Fletcher,et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging , 2013, The American Journal of Gastroenterology.
[4] A. Schoepfer,et al. Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes , 2013, Inflammatory bowel diseases.
[5] G. Zararsiz,et al. Neutrophil–Lymphocyte Ratio as a Predictor of Disease Severity in Ulcerative Colitis , 2013, Journal of clinical laboratory analysis.
[6] T. Kim,et al. Correlations of C-reactive Protein Levels and Erythrocyte Sedimentation Rates with Endoscopic Activity Indices in Patients with Ulcerative Colitis , 2013, Digestive Diseases and Sciences.
[7] B. Shirts,et al. The Entire Predictive Value of the Prometheus IBD sgi Diagnostic Product May be Due to the Three Least Expensive and Most Available Components , 2012, The American Journal of Gastroenterology.
[8] Y. Beyazit,et al. Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity. , 2012, Clinics and research in hepatology and gastroenterology.
[9] M. Ciorba,et al. Biomarkers in inflammatory bowel disease: current practices and recent advances. , 2012, Translational research : the journal of laboratory and clinical medicine.
[10] E. Pamer,et al. Monocyte recruitment during infection and inflammation , 2011, Nature Reviews Immunology.
[11] T. Macdonald,et al. Regulation of homeostasis and inflammation in the intestine. , 2011, Gastroenterology.
[12] J. Lewis. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. , 2011, Gastroenterology.
[13] J. Gisbert,et al. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. , 2009, Inflammatory bowel diseases.
[14] M. Silverberg,et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] L. Cleland,et al. Treatment‐induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis , 2009, Internal medicine journal.
[16] B. Zhong,et al. Significance of white blood cell count and its subtypes in patients with acute coronary syndrome , 2009, European journal of clinical investigation.
[17] J. Ellenberg,et al. Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.
[18] A. Michalsen,et al. Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.
[19] K. Faber,et al. Monocytes and their pathophysiological role in Crohn’s disease , 2008, Cellular and Molecular Life Sciences.
[20] P. Rutgeerts,et al. Laboratory markers in IBD: useful, magic, or unnecessary toys? , 2006, Gut.
[21] A. Zinsmeister,et al. Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.
[22] Y. Saeki,et al. Long-Term Follow-Up of the Changes in Circulating Cytokines, Soluble Cytokine Receptors, and White Blood Cell Subset Counts in Patients with Rheumatoid Arthritis (RA) After Monoclonal Anti-TNFα Antibody Therapy , 1999, Journal of Clinical Immunology.
[23] C. Seal,et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis , 2001, American Journal of Gastroenterology.
[24] S. Targan,et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease , 2001, American Journal of Gastroenterology.
[25] Y. Saeki,et al. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. , 1999, Journal of clinical immunology.
[26] E. Irvine,et al. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. , 1996, The American journal of gastroenterology.
[27] W. Tremaine,et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.
[28] C. Smith,et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. , 1986, Gut.
[29] D. Jewell,et al. Monocytes in inflammatory bowel disease: absolute monocyte counts. , 1980, Journal of clinical pathology.
[30] C. Charland,et al. The subpopulations of circulating white blood cells in inflammatory bowel disease. , 1976, Gastroenterology.